• AWS Architecture Blog How Artera enhances prostate cancer diagnostics using AWS This post was co-written with Hariharan Ananthakrishnan from Artera. • Artificial intelligence (AI) and machine learning (ML) are transforming cancer diagnosis and treatment, enabling faster and more accurate decisions for patients. • One company at the forefront of this transformation is Artera, a precision medicine company developing an AI-powered platform for cancer treatment planning. • Food and Drug Administration (FDA) has granted De Novo authorization for the ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes for patients with nonmetastatic prostate cancer. • The ArteraAI Prostate is now recognized as an FDA-regulated software as a medical device (SaMD). • In this post, we explore how Artera used Amazon Web Services (AWS) to develop and scale their AI-powered prostate cancer test, accelerating time to results and enabling personalized treatment recommendations for patients.
Article Summaries:
- Artera has leveraged Amazon Web Services to accelerate the development and deployment of its AI‑powered ArteraAI Prostate test, a diagnostic tool that predicts long‑term outcomes for patients with non‑metastatic prostate cancer. The platform, now FDA‑regulated as a software‑as‑a‑medical‑device (SaMD) following De Novo authorization, is the first AI system approved to prognosticate therapeutic benefit in localized disease. Included in National Comprehensive Cancer Network guidelines, the test analyzes biopsy images to stratify risk and guide treatment decisions, aiming to reduce overtreatment and improve patient outcomes. AWS’s scalable infrastructure enables rapid processing and timely delivery of results to pathology labs worldwide.
Sources: